Galmed Pharmaceuticals Allocates 50% of Cash Reserves to Crypto
- Galmed shifts 50% cash reserves to digital assets.
- Biopharma enters crypto treasury diversification.
- Engages Tectona to manage digital assets.
Galmed Pharmaceuticals is investing up to $5 million in digital assets, aiming for diversification in treasury management. This decision involves DeFi strategies such as staking and liquidity provision, advised by Tectona Ltd., positioning them uniquely in the biopharma industry.
Galmed Pharmaceuticals, a clinical-stage biopharma based in Tel Aviv, announced a new strategy on August 25, 2025, allocating 50% of its $10 million reserves to digital assets. This unprecedented move for the biopharma sector includes engaging Tectona Ltd. for implementation.
Galmed’s strategic decision signals a bold diversification plan in financial management, aiming to improve treasury yields through crypto markets. The move represents a significant pivot from traditional cash management in the biopharma industry.
Galmed Pharmaceuticals’ Board has approved a digital asset strategy, adjusting 50% of cash for crypto diversification, marking an industry first. The leadership has engaged Tectona Ltd. for advisory and implementation roles. This shift aims to enhance capital management practices through innovative means.
The involvement of Tectona Ltd. , a Treasury management service provider, plays a crucial role in executing this digital asset allocation. Galmed is now among the first biopharma companies diversifying in cryptocurrency, ensuring strategic council and management oversight with its newly formed Crypto Committee.
The company’s shift translates to potential market impacts on liquidity and yields, particularly in decentralized finance (DeFi) sectors. Staking and lending protocols, synonymous with ETH and BTC, are likely focal points in Galmed’s pursuits, driven by a need for higher yields.Finance-wise, the allocation to digital assets may yield higher returns but comes with greater volatility. Political scrutiny and regulatory pressures are expected to rise as biopharma companies generally have less precedent in crypto exposure compared to tech sectors.
Galmed Pharmaceuticals commented on their shift, emphasizing:
“Innovation and careful strategy balancing are crucial for future success.”
Galmed’s move into the digital assets arena could pave the way for more biopharma companies considering similar strategies. Technological and regulatory landscapes might evolve, signaling a growing acceptance of crypto in non-tech sectors. Innovation and careful strategy balancing are crucial for future success.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ethereum News Today: BlockDAG's $385M Presale Quietly Challenges Top Crypto Giants
- BlockDAG's $385M presale sold 25.5B tokens, attracting 2.5M mobile miners and 19K hardware miners. - Hybrid DAG+PoW architecture with EVM compatibility supports 4.5K developers and 300+ dApps in development. - Strategic sports partnerships (Inter Milan, Seattle teams) boost visibility through fan tokens and stadium integrations. - Analysts project $0.05 listing price with potential to reach $1-$10, challenging Ethereum and Solana's dominance.

Bitcoin News Today: Bitcoin Gets a Wallet Upgrade: USDT Joins BTC Natively via RGB
- Tether plans to deploy USDT on RGB protocol, enabling private Bitcoin-based stablecoin transactions. - Integration allows users to store and transfer USDT alongside BTC in the same wallet, enhancing privacy and usability. - RGB's client-side validation reduces on-chain data, supporting offline transactions and Lightning Network integration. - This move positions Bitcoin as a functional payment network, expanding use cases like cross-border remittances. - Experts suggest it could reduce reliance on altern

Bitcoin News Today: Bitcoin's Bull Trap Unfolds as Momentum Fades and Capital Flees
- Bitcoin's price fell to a seven-week low of $108,700 after peaking at $124,000, with analysts warning of a potential bull trap as RSI divergence signals weakening momentum. - Key support levels at $107,000 and $100,000 (aligned with the 200-day moving average) face retests, while $117,000 resistance remains critical for short-term reversal hopes. - Over $1B in Bitcoin ETF outflows and a $11.4B institutional shift to Ethereum highlight capital reallocation, compounding pressure amid Fed rate uncertainty a

Ethereum's Supply Dynamics and Whale Exposure: A Critical Juncture for ETH Bulls
- Ethereum's post-Merge deflationary model combines 2.95% staking yields with EIP-1559 burns, creating a supply vacuum as 30% of ETH is staked. - Whale concentration (74.97% supply control) and $6B Q3 2025 exchange withdrawals highlight liquidity risks amid macroeconomic volatility. - SEC's 2025 utility token reclassification boosted institutional adoption ($9.4B ETF inflows), but $3.7B queued withdrawals signal market fragility. - Mega whales increased holdings by 9.31% since October 2024, consolidating i

Trending news
MoreCrypto prices
More








